Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AGIO
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.79 billion
  • Outstanding Shares: 48,391,000
Average Prices:
  • 50 Day Moving Avg: $57.35
  • 200 Day Moving Avg: $52.65
  • 52 Week Range: $35.84 - $67.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.99
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $53.49 million
  • Price / Sales: 52.13
  • Book Value: $10.53 per share
  • Price / Book: 5.47
  • EBIDTA: ($266,250,000.00)
  • Net Margins: -502.12%
  • Return on Equity: -68.15%
  • Return on Assets: -41.17%
  • Current Ratio: 6.46%
  • Quick Ratio: 6.46%
  • Average Volume: 519,184 shs.
  • Beta: 1.94
  • Short Ratio: 16.59

Frequently Asked Questions for Agios Pharmaceuticals (NASDAQ:AGIO)

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($1.78) EPS for the quarter, missing the Zacks' consensus estimate of ($1.57) by $0.21. The firm earned $11.30 million during the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The firm's revenue for the quarter was up 62.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.47) earnings per share. View Agios Pharmaceuticals' Earnings History.

When will Agios Pharmaceuticals make its next earnings announcement?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Agios Pharmaceuticals.

Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2017?

10 brokerages have issued twelve-month price targets for Agios Pharmaceuticals' shares. Their predictions range from $57.00 to $90.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $74.75 in the next twelve months. View Analyst Ratings for Agios Pharmaceuticals.

What are analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

  • 1. Cann analysts commented, "This dinner and discussion with management, experts, and investors offered an update on AG-120 and an in-depth look at AG-221. Takeaways for AG-221 focused on outcomes and commercial use. AG-221 was found to have remarkable outcomes, especially in light of the difficult-to-treat population in the study. The enthusiasm expressed by Drs." (6/11/2017)
  • 2. According to Zacks Investment Research, "Agios's shares have outperformed the Medical-Products industry so far this year. As a development-stage company, Agios depends heavily on Celgene for revenues. However, the collaboration with Celgene is encouraging as it provides Agios funds in the form of upfront, regulatory and commercial milestone payments plus royalties. In terms of the company’s pipeline, most of the candidates are in mid and early stages of development and thus, several years away from entering the market. Moreover, the decision to discontinue the development of AG-519 is disappointing. Stiff competition is another matter of concern for the company. Estimates have been going down lately ahead of the company’s Q1 earnings release. The company has mixed record of earnings surprises in recent quarters." (4/28/2017)
  • 3. Cowen and Company analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)

Who are some of Agios Pharmaceuticals' key competitors?

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:

  • David P. Schenkein M.D., President, Chief Executive Officer, Director
  • Andrew Hirsch, Chief Financial Officer
  • Scott Biller Ph.D., Chief Scientific Officer
  • Christopher Bowden M.D., Chief Medical Officer
  • Steven L. Hoerter, Chief Commercial Officer
  • Lewis Clayton Cantley Ph.D., Director
  • David Scadden M.D., Director
  • Paul J. Clancy, Independent Director
  • Ian T. Clark, Independent Director
  • Kaye I. Foster-Cheek, Independent Director

Who owns Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (14.99%), Vanguard Group Inc. (6.67%), Capital International Investors (6.47%), BB Biotech AG (5.95%), BlackRock Inc. (5.55%) and State Street Corp (2.69%). Company insiders that own Agios Pharmaceuticals stock include Celgene European Investment Co, David P Schenkein, Glenn Goddard, John Duncan Higgons, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Institutional Ownership Trends for Agios Pharmaceuticals.

Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Capital Guardian Trust Co., Columbus Circle Investors, Quantitative Investment Management LLC, JPMorgan Chase & Co., Fiera Capital Corp, Nationwide Fund Advisors and Paradigm Asset Management Co. LLC. Company insiders that have sold Agios Pharmaceuticals stock in the last year include David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Insider Buying and Selling for Agios Pharmaceuticals.

Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., BlackRock Inc., Janus Henderson Group PLC, First Trust Advisors LP, Capital International Investors, PDT Partners LLC and AXA. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy Agios Pharmaceuticals stock?

Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of Agios Pharmaceuticals stock can currently be purchased for approximately $57.62.

MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.90)
Consensus Price Target: $74.75 (29.73% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$75.00 -> $83.00LowView Rating Details
8/10/2017Needham & Company LLCBoost Price TargetBuy -> Buy$54.00 -> $72.00MediumView Rating Details
8/8/2017Canaccord GenuitySet Price TargetBuy$90.00LowView Rating Details
8/8/2017SunTrust Banks, Inc.Reiterated RatingBuy -> Buy$68.00 -> $80.00LowView Rating Details
8/2/2017Leerink SwannUpgradeMarket Perform -> Outperform$50.00 -> $80.00HighView Rating Details
8/1/2017Janney Montgomery ScottReiterated RatingHoldHighView Rating Details
6/11/2017CannReiterated RatingBuy$75.00MediumView Rating Details
4/18/2017Credit Suisse GroupReiterated RatingOutperform$61.00HighView Rating Details
2/16/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
1/17/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageNeutralN/AView Rating Details
8/10/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$46.00N/AView Rating Details
6/13/2016J P Morgan Chase & CoUpgradeNeutral -> Overweight$50.00 -> $62.00N/AView Rating Details
11/9/2015Roth CapitalLower Price TargetNeutral$114.00 -> $75.00N/AView Rating Details
(Data available from 8/23/2015 forward)


Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)
Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Earnings History by Quarter for Agios Pharmaceuticals (NASDAQ AGIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($1.78)N/AView Earnings Details
8/8/2017Q2 2017($1.57)($1.78)$10.68 million$11.30 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.80)($1.56)$9.65 million$10.51 millionViewListenView Earnings Details
2/16/2017Q416($1.51)($1.34)$10.89 million$22.65 millionViewListenView Earnings Details
11/3/2016Q316($1.52)($1.63)$7.82 million$8.98 millionViewListenView Earnings Details
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.27)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.86)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.55)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 million$33.90 millionViewListenView Earnings Details
8/7/2014Q2($0.47)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.37)($0.39)$7.19 million$8.41 millionViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)
2017 EPS Consensus Estimate: ($7.07)
2018 EPS Consensus Estimate: ($7.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.86)($1.78)($1.81)
Q2 20173($1.91)($1.48)($1.73)
Q3 20173($1.99)($1.50)($1.76)
Q4 20173($2.04)($1.52)($1.78)
Q1 20181($2.31)($2.31)($2.31)
Q2 20181($2.31)($2.31)($2.31)
Q3 20181($2.45)($2.45)($2.45)
Q4 20181($0.21)($0.21)($0.21)
(Data provided by Zacks Investment Research)


Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Agios Pharmaceuticals (NASDAQ:AGIO)
Insider Ownership Percentage: 10.55%
Institutional Ownership Percentage: 83.13%
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2017David P SchenkeinCEOSell27,000$59.95$1,618,650.00View SEC Filing  
8/2/2017Scott BillerInsiderSell23,146$59.60$1,379,501.60View SEC Filing  
7/20/2017Lewis Clayton Jr. CantleyDirectorSell9,000$56.36$507,240.00View SEC Filing  
7/19/2017Lewis Clayton Jr. CantleyDirectorSell3,500$56.14$196,490.00View SEC Filing  
7/7/2017Scott BillerInsiderSell2,146$55.00$118,030.00View SEC Filing  
7/3/2017David P SchenkeinCEOSell3,000$51.18$153,540.00View SEC Filing  
6/21/2017Scott BillerInsiderSell4,292$55.00$236,060.00View SEC Filing  
6/14/2017Lewis Clayton Jr. CantleyDirectorSell2,000$50.87$101,740.00View SEC Filing  
6/7/2017David P SchenkeinCEOSell3,000$50.02$150,060.00View SEC Filing  
5/25/2017Lewis Clayton Jr. CantleyDirectorSell2,036$47.10$95,895.60View SEC Filing  
5/1/2017David P SchenkeinCEOSell3,000$50.06$150,180.00View SEC Filing  
4/24/2017Celgene European Investment CoMajor ShareholderBuy624,575$49.50$30,916,462.50View SEC Filing  
4/18/2017Lewis Clayton Jr. CantleyDirectorSell5,090$54.37$276,743.30View SEC Filing  
4/17/2017Lewis Clayton Jr. CantleyDirectorSell2,036$55.24$112,468.64View SEC Filing  
4/3/2017David P SchenkeinCEOSell3,000$58.62$175,860.00View SEC Filing  
4/3/2017Scott BillerInsiderSell2,146$58.03$124,532.38View SEC Filing  
3/23/2017Lewis Clayton Jr. CantleyDirectorSell2,036$53.11$108,131.96View SEC Filing  
3/20/2017Scott BillerInsiderSell6,438$55.00$354,090.00View SEC Filing  
3/6/2017Robert NelsenDirectorSell40,599$50.84$2,064,053.16View SEC Filing  
2/28/2017Robert NelsenDirectorSell243,082$49.36$11,998,527.52View SEC Filing  
2/23/2017Robert NelsenDirectorSell135,364$49.37$6,682,920.68View SEC Filing  
2/16/2017David P SchenkeinCEOSell6,000$50.01$300,060.00View SEC Filing  
10/27/2016Lewis Clayton Jr. CantleyDirectorSell2,504$48.94$122,545.76View SEC Filing  
10/5/2016Scott BillerInsiderSell5,000$55.00$275,000.00View SEC Filing  
9/28/2016Lewis Clayton Jr. CantleyDirectorSell627$54.00$33,858.00View SEC Filing  
9/27/2016Lewis Clayton Jr. CantleyDirectorSell627$54.15$33,952.05View SEC Filing  
9/20/2016Scott BillerInsiderSell5,000$50.00$250,000.00View SEC Filing  
8/30/2016Lewis Clayton Jr. CantleyDirectorSell627$36.81$23,079.87View SEC Filing  
8/29/2016Lewis Clayton Jr. CantleyDirectorSell627$37.81$23,706.87View SEC Filing  
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.00View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.00View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.00View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.00View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.00View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.00View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.00View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.00View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.00View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Agios Pharmaceuticals (NASDAQ:AGIO)
Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)
DateHeadline logoAgios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : August 18, 2017 - August 18 at 3:48 PM logoAgios Pharmaceuticals, Inc. (AGIO) Given Consensus Recommendation of "Buy" by Brokerages - August 18 at 12:48 PM logoSee what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc. - August 14 at 9:02 PM logoAgios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y - Nasdaq - August 11 at 4:07 PM logoLeerink Swann Comments on Agios Pharmaceuticals, Inc.'s FY2017 Earnings (NASDAQ:AGIO) - August 11 at 12:02 PM logoAgios Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($1.78) Per Share, SunTrust Banks Forecasts (NASDAQ:AGIO) - August 10 at 12:10 PM logoQ3 2017 Earnings Forecast for Agios Pharmaceuticals, Inc. Issued By Oppenheimer Holdings (NASDAQ:AGIO) - August 10 at 12:10 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc. - August 10 at 11:44 AM logoAgios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y - August 9 at 3:49 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) to Post FY2020 Earnings of $3.10 Per Share, Oppenheimer Holdings Forecasts - August 9 at 3:02 PM logoEdited Transcript of AGIO earnings conference call or presentation 8-Aug-17 12:00pm GMT - August 9 at 1:42 AM logoAgios Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release) - August 8 at 8:37 PM logoIs a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season? - Nasdaq - August 8 at 8:37 PM logoAgios (AGIO) Q2 Loss Wider than Expected; Sales Miss - Nasdaq - August 8 at 8:37 PM logoAgios: Smooth First Mover In Cancer Metabolism - Seeking Alpha - August 8 at 8:37 PM logoAgios Pharmaceuticals, Inc. (AGIO) Given a $90.00 Price Target at Canaccord Genuity - August 8 at 6:26 PM logoAgios Pharmaceuticals' (NASDAQ:AGIO) "Buy" Rating Reaffirmed at SunTrust Banks, Inc. - August 8 at 5:44 PM logoBRIEF-Agios posts Q2 loss per share $1.78‍ - August 8 at 3:34 PM logoAgios Pharmaceuticals, Inc. 2017 Q2 - Results - Earnings Call Slides - August 8 at 3:34 PM logoAgios Reports Second Quarter 2017 Financial Results - August 8 at 3:34 PM logoAgios (AGIO) Q2 Loss Wider than Expected; Sales Miss - August 8 at 3:34 PM logoAgios Pharmaceuticals reports 2Q loss - August 8 at 3:34 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Posts Earnings Results, Misses Expectations By $0.21 EPS - August 8 at 9:00 AM logoIs a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season? - August 7 at 4:34 PM logoMed-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More - August 7 at 4:34 PM logo4 Medical Product Stocks Likely to Top Q2 Earnings Estimates - August 7 at 4:34 PM logo Brokerages Expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Will Post Quarterly Sales of $11.52 Million - August 7 at 8:32 AM logo-$1.51 EPS Expected for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) This Quarter - August 5 at 8:36 PM logoAgios Pharmaceuticals, Inc. (AGIO) Forecasted to Earn Q2 2017 Earnings of ($1.48) Per Share - August 4 at 7:16 AM logoAgios Pharmaceuticals, Inc. (AGIO) Insider Sells $1,379,501.60 in Stock - August 3 at 7:52 PM logoDavid P. Schenkein Sells 27,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock - August 3 at 7:50 PM logoAgios Pharmaceuticals Reaches Analyst Target Price - August 3 at 4:41 PM
News IconA small biotech behind a groundbreaking approach to tackling cancer just got its first drug approved - Business Insider - August 3 at 4:41 PM logoAgios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session - Nasdaq - August 3 at 4:41 PM logoCelgene CEO: Precision medicine targeting metabolic drive... - August 3 at 4:41 PM logoAgios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session - August 3 at 4:41 PM logoAgios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017 - August 3 at 4:41 PM logoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given a $90.00 Price Target at Canaccord Genuity - August 2 at 6:28 PM logoBenzinga's Top Upgrades, Downgrades For August 2, 2017 - Benzinga - August 2 at 3:32 PM logoThis Small Biotech Launched To A 9-Month High Today — Here's Why - August 2 at 3:32 PM logoA small biotech behind a groundbreaking approach to tackling cancer just got its first drug approved - August 1 at 4:38 PM logoA small biotech behind a groundbreaking approach to tackling cancer just got its first drug approved - August 1 at 4:38 PM logoAgios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017 - GlobeNewswire (press release) - July 28 at 3:57 PM logoAgios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017 - July 28 at 8:32 AM logoRevlimid drives Celgene profit beat; raises EPS forecast - July 27 at 3:49 PM logoCommit To Purchase Agios Pharmaceuticals At $45, Earn 10.9% Annualized Using Options - Nasdaq - July 26 at 3:38 PM logoWhat's in Store for Agios Pharma (AGIO) in Q2 Earnings? - July 26 at 3:38 PM logoAgios Pharmaceuticals, Inc. (AGIO) Scheduled to Post Quarterly Earnings on Wednesday - July 26 at 7:12 AM logoAgios Pharmaceuticals, Inc. (AGIO) Given Average Rating of "Buy" by Brokerages - July 24 at 12:11 PM logoAgios Pharmaceuticals, Inc. (AGIO) Director Sells $196,490.00 in Stock - July 21 at 7:31 PM



Agios Pharmaceuticals (AGIO) Chart for Wednesday, August, 23, 2017

This page was last updated on 8/23/2017 by Staff